Related Experiment Video
Updated: Dec 31, 2025
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
O-GlcNAcylation as a Therapeutic Target for Alzheimer's Disease
Jinsu Park1,2, Mitchell K P Lai3, Thiruma V Arumugam4,5,6
1School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Korea.
Abstract:
Alzheimer's disease (AD) is the most common cause of dementia and the number of elderly patients suffering from AD has been steadily increasing. Despite worldwide efforts to cope with this disease, little progress has been achieved with regard to identification of effective therapeutics. Thus, active research focusing on identification of new therapeutic targets of AD is ongoing. Among the new targets, post-translational modifications which modify the properties of mature proteins have gained attention. O-GlcNAcylation, a type of PTM that attaches O-linked β-N-acetylglucosamine (O-GlcNAc) to a protein, is being sought as a new target to treat AD pathologies. O-GlcNAcylation has been known to modify the two important components of AD pathological hallmarks, amyloid precursor protein, and tau protein. In addition, elevating O-GlcNAcylation levels in AD animal models has been shown to be effective in alleviating AD-associated pathology. Although studies investigating the precise mechanism of reversal of AD pathologies by targeting O-GlcNAcylation are not yet complete, it is clearly important to examine O-GlcNAcylation regulation as a target of AD therapeutics. This review highlights the mechanisms of O-GlcNAcylation and its role as a potential therapeutic target under physiological and pathological AD conditions.
Insights
Alzheimer's disease (AD) research is exploring O-GlcNAcylation, a protein modification, as a novel therapeutic target. Enhancing O-GlcNAcylation shows promise in animal models for alleviating AD pathology.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Alzheimer's disease (AD) is the leading cause of dementia, with increasing prevalence and limited therapeutic options.
- Post-translational modifications (PTMs) are emerging as critical regulators of protein function and potential therapeutic targets.
- O-GlcNAcylation, a PTM adding O-linked β-N-acetylglucosamine (O-GlcNAc), is gaining attention for its role in AD.
Purpose of the Study:
- To review the mechanisms of O-GlcNAcylation.
- To explore the role of O-GlcNAcylation as a potential therapeutic target in Alzheimer's disease.
- To highlight O-GlcNAcylation's impact on AD pathological hallmarks.
Main Methods:
- Literature review of studies on O-GlcNAcylation in AD.
- Analysis of O-GlcNAcylation's effects on amyloid precursor protein and tau protein.
- Examination of AD animal models with altered O-GlcNAcylation levels.
Main Results:
- O-GlcNAcylation modifies key AD pathological components: amyloid precursor protein and tau protein.
- Elevated O-GlcNAcylation levels in AD animal models demonstrated efficacy in reducing AD-associated pathology.
- O-GlcNAcylation is implicated in regulating cellular processes relevant to AD.
Conclusions:
- O-GlcNAcylation represents a promising therapeutic target for Alzheimer's disease.
- Further research into the precise mechanisms of O-GlcNAcylation in reversing AD pathologies is warranted.
- Targeting O-GlcNAcylation offers a novel strategy for developing effective AD therapeutics.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:19Ligand-gated Ion Channels
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...